Novesine (Oxybuprocaine Hydrochloride)

Oxybuprocaine hydrochloride blocks voltage‑gated sodium channels in peripheral nerve membranes of the cornea. By preventing the initiation and propagation of nerve impulses, it temporarily halts sensory transmission, producing rapid, localized anesthesia of the eye without affecting systemic nerve function.

The appropriate dose of Novesine is determined by the prescribing clinician based on the specific diagnostic or procedural need. Typically, a single drop is instilled onto the ocular surface, but the exact regimen should follow the healthcare professional’s instructions.

Safety data for oxybuprocaine hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Novesine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Novesine (oxy­buprocaine) provides rapid onset and short duration of surface anesthesia, similar to other ester‑type ophthalmic anesthetics such as proparacaine. Compared with amide‑type agents, oxybuprocaine has a slightly faster onset but may be associated with a higher incidence of transient ocular irritation.

Novesine should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct light and moisture, and keep the vial tightly closed when not in use to maintain sterility and potency.

Novesine is applied topically to the eye. The prescriber typically instills a single drop onto the conjunctival sac, allowing the solution to spread over the corneal surface. The patient should avoid blinking excessively for a few seconds to ensure adequate coverage.

Serious risks, though rare, include allergic reactions such as rash, swelling, or anaphylaxis, as well as corneal ulceration or persistent epithelial defects. Any signs of severe ocular irritation, vision loss, or systemic symptoms should prompt immediate medical evaluation.

Novesine should not be used in individuals with a known hypersensitivity to oxybuprocaine, other local anesthetics of the ester type, or any component of the formulation. It is also contraindicated in patients with active corneal infections or severe ocular surface disease unless specifically directed by a clinician.